Cargando…

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases

In 2018, Baricitinib was approved by the Food and Drig Administration (FDA) for the treatment of rheumatoid arthritis. Baricitinib exerts its action by targeting Janus kinases (JAK). In this study, we describe the necessary steps for preparing the drug using two alternative routes.

Detalles Bibliográficos
Autores principales: Mayence, Annie, Vanden Eynde, Jean Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469186/
https://www.ncbi.nlm.nih.gov/pubmed/30871014
http://dx.doi.org/10.3390/ph12010037